HOW THIS WORKS: most trials in our database only care about some (not all) of the questions. When you answer a question, we look to see which trials in our database consider that question relevant. If your answer matches what any of those trials are looking for, we increase those trials' "relevance" scores by 1 in the table of results. If your answer doesn't match what a trial is looking for, then that trial will not be displayed. The best way to narrow down the results below is by answering all of the questions.
TRIAL DATA LAST UPDATED: 2023-08-07 16:29:18
TRIAL DATA LAST UPDATED: 2023-08-07 16:29:18
Matching Clinical Trials(no questions answered yet)
Description | Location(s) | Relevance |
---|---|---|
A Randomized Phase II Study Comparing Sequential High Dose Testosterone and Enzalutamide to Enzalutamide Alone in Asymptomatic Men With Castration Resistant Metastatic Prostate Cancer (J2060)
read more
Asymptomatic men without pain due to prostate cancer progressing with metastatic castrate resistant prostate cancer (mCRPC) after treatment with combination or sequential ADT (androgen deprivation therapy, a type of hormonal therapy) + Abiraterone (Zytiga, a type of hormonal therapy) will be treated on a randomized, open label study to determine if sequential treatment with high dose testosterone (a hormone) and Enzalutamide (Xtandi, a type of hormonal therapy) will improve progression free survival (PFS) versus continuous Enzalutamide alone as standard therapy.
This study has 2 arms:
Arm A: Enzalutamide alone
Patients randomized to Arm A will receive continuous therapy with standard dose Enzalutamide 160 mg taken by mouth (orally or po) daily.
Arm B: Testosterone + Enzalutamide
Patients randomized to Arm B will receive an intramuscular (IM) injection with testosterone cypionate or testosterone enanthate at a dose of 400 mg every 56 days, followed by Enzalutamide 160 mg taken by mouth daily.
|
JHUH, SMH | 0 |
PROMISE Registry: A Prostate Cancer Registry of Outcomes and Germline Mutations for Improved Survival and Treatment Effectiveness
read more
PROMISE aims to create a comprehensive nationwide registry of prostate cancer patients with germline pathogenic variants (targetable mutations) by screening approximately 5,000 subjects with a confirmed prostate cancer diagnosis, either through tissue biopsy, PSA greater than 100 ng/dL and/or radiographic evidence of disease and receiving systemic therapy for prostate cancer. Patients at all stages of disease will be welcome to participate in the PROMISE Registry.
Participants will be recruited and screened over a five-year period. Study participants will be asked to provide a saliva sample to be tested for germline cancer risk variants through Color Health. If the results identify a pathogenic or likely pathogenic variant, an appointment with a genetic counselor from Color Health will be scheduled to discuss the results.
Participants will complete a baseline demographic survey that includes self-reported health history, family history of cancer and standardized patient reported outcome (PRO) measures.
PROMISE Registry staff will request medical records from the participant's cancer care provider(s) for the purpose of obtaining clinical data.
Participants will receive bi-annual newsletters offering information on new developments in treatment and research opportunities, including clinical trials, associated with genetic variants.
Eligible participants (those with target germline mutations) will be followed every 6 months to obtain updated health records data and patient-reported outcomes data. Participants will be followed for a minimum of 15 years.
The PROMISE registry will help identify prostate cancer patients with pathogenic variants to learn more about how these variants affect patient outcomes. Ultimately, we hope to help patients learn more about their disease and the treatments that they may derive the most benefit from, including the germline genetic biomarker-based clinical trials they may be eligible for.
There is no treatment given as part of this study – it is a registry only.
|
JHUH | 0 |
A Phase 1/2 Study of EPI-7386 in Combination With Enzalutamide Compared With Enzalutamide Alone in Subjects With Metastatic Castration-Resistant Prostate Cancer (J# pending)
read more
This is a Phase 1/2 study of EPI-7386 (a type of hormonal therapy) orally administered in combination with enzalutamide (Xtandi, a type of hormonal therapy) in subjects with metastatic castration-resistant prostate cancer (mCRPC).
Phase 1 of the study will be a single-arm dose escalation study of EPI-7386 in combination with a fixed dose of enzalutamide. This portion of the study will primarily evaluate the safety and tolerability of the drug combination and establish the recommended dose for EPI-7386 and enzalutamide when dosed in combination. In addition, blood sampling will be conducted for evaluation to assess the potential interaction between the two drugs.
This study has 2 treatment arms:
Arm A: EPI-7386 + Enzalutamide
EPI-7386 given by mouth (PO, orally) at varying dose levels PLUS Enzalutamide given by mouth at 120 mg or 160 mg.
Arm B: Enzalutamide alone
Enzalutamide given by mouth at 160 mg.
|
JHUH, SMH | 0 |
Whole-Food Plant-Based Diet (WFPBD) to Control Weight and Metabo-Inflammation in Overweight/Obese Men With Prostate Cancer Receiving Androgen Deprivation Therapy (ADT) (J2276)
read more
The study is comparing the effect on weight of providing home-delivered whole-food, plant-based meals versus standard, general nutritional counseling to men with prostate cancer on androgen-deprivation therapy (ADT, hormonal therapy).
Prostate cancer is the most common cancer diagnosis for men in the United States. For patients with advanced or recurrent disease, ADT has is the cornerstone of systemic treatment. Overall, almost half of prostate cancer patients will undergo ADT at some point during their treatment. Unfortunately, ADT has metabolic side effects, including weight gain, central adiposity (fat around your middle/stomach area), and insulin resistance. This study is a multi-site randomized phase II trial comparing a home-delivered whole food, plant-based diet (WFPBD) with specialized behavioral coaching to standard dietary intervention with general nutritional counseling to assess the efficacy of a WFPBD in promoting weight loss in overweight/obese men receiving ADT. The home-delivered WFPBD will be for 28 days with 12 meals a week followed by 28 days with 6 meals a week; followed by self-prepared WFPBD for 18 weeks (for a total of 26 weeks).
The study hypothesis is that a WFPBD will decrease body weight and decrease systemic metabo-inflammation (inflammation caused by excessive weight) in overweight/obese men (BMI > 27) with prostate cancer receiving ADT. Secondary objectives will be to assess the effects of a WFPBD on adiposity, markers of inflammation, and fecal microbiota (gut or GI tract bacteria) that may contribute to prostate cancer progression; to assess the effects of a WFPBD on quality of life; and to assess the durability of any observed effect of the intervention after cessation of the meal-delivery service.
This study has 2 treatment arms:
Arm A: Whole-food, Plant-Based Diet
Pre-packaged, plant-based meals (prepared by Plantable) will be delivered weekly to participants' homes for 8 weeks. Meals are made with whole ingredients including whole grains, vegetables, legumes, nuts and seeds. Added sugar, animal-based products, refined grains, and processed foods are not used in any meal. Participants will be coached by phone calls, texts, emails, and the app throughout the intervention to prepare meals in accordance with the diet. Participants will have access to a Registered Dietitian. During the first 4 weeks, 12 meals/week will be provided to participants; followed by 6 meals/week for the next 4 weeks; followed by 18 weeks where participants will continue to receive coaching but will be expected to make all their own whole-food, plant-based meals using Plantable's assistance.
Arm B: General Nutritional Counseling
All study participants will receive consult with a Registered Dietitian at the Baseline visit and visit 1 study assessments. After visit 1, study participants assigned to the general nutritional counseling arm will receive an additional in-person or telehealth consultation with a Registered Dietitian that will consist of identification and counseling to improve diet quality and achieve a healthy body weight consistent with American Cancer Society guidelines.
Study participants in the control group will continue to receive general nutritional counseling and education with weekly scheduled telephone consultations with a Registered Dietitian for the first 4 weeks of the study period. For the remainder of the study period, they will receive counseling and education from Registered Dietitians via monthly scheduled phone calls.
|
JHUH, SMH | 0 |
Bipolar Androgen Therapy (BAT) and Radium-223 (RAD) in Metastatic Castration-resistant Prostate Cancer (mCRPC) (BAT-RAD Study)
read more
This is a study of Bipolar Androgen Therapy (BAT, a type of hormonal therapy) plus Radium-223 (RAD, a type of bone targeted therapy) in men with metastatic castration-resistant prostate cancer (mCRPC). Men with mCRPC with progressive disease (radiographically and/or biochemically) who have been treated with gonadotropin-releasing hormone (GnRH)-analogue (LHRH agonists/antagonists) continuously or bilateral orchidectomy will be enrolled in this study. Previous antiandrogen therapies are permitted, but no more than one (such as abiraterone, enzalutamide, apalutamide, darolutamide).
All patients will receive treatment with Radium-223 at a dose of 55 Kilobecquerel (kBq) per kilogram of body weight intravenously (IV) every 28 days, for 6 cycles, plus Testosterone Cypionate 400mg Intramuscular (IM) every 28 days, until progression or unacceptable toxicity.
|
SMH | 0 |
A Phase II Study Assessing the Safety and Efficacy of Oral Testosterone Undecanoate Followed by Enzalutamide as Therapy for Men With Metastatic Castrate Resistant Prostate Cancer (J2178)
read more
Previous studies of high dose testosterone (a type of hormone) therapy given intramuscularly (IM, injection) to men with metastatic castrate resistant prostate cancer suggest that high serum levels of testosterone may be required for clinical response.
This trial will analyze the effects of oral testosterone therapy in men with metastatic castrate resistant prostate cancer taken on a schedule of seven days of oral testosterone therapy followed by seven days of no therapy for a twenty-eight day cycle. This therapy will be given for three 28 day cycles consecutively followed by radiographic scans to evaluate the metastatic disease. Patients will be allowed to continue on this therapy until the patients show signs of radiographic progression. If the patients show signs of radiographic progression after the first three cycles, the patients will stop taking the oral testosterone therapy and begin taking enzalutamide (Xtandi, a type of hormonal therapy) therapy. Enzalutamide therapy will be taken for three 28 day cycles, then radiographic scans will be taken. If there are no signs of radiographic progression, patients can continue to take enzalutamide therapy for an additional 3 cycles while on study. Patients with continued PSA or objective response will come off study but continue on enzalutamide as standard of care therapy.
This study will help the investigators to understand if treating these men with the highest FDA approved dose of oral testosterone therapy will achieve similar and sustained high levels of serum testosterone that will produce similar or enhanced therapeutic response to the therapy when compared to the serum testosterone levels found in the previous injection therapy trials.
This study has 1 treatment arm:
Oral Testosterone Therapy given until radiographic progression followed by Enzalutamide Therapy
Oral Testosterone Therapy, 396 mg given by mouth (PO, orally) twice per day on days 1-7 and 15-21 of a 28 day cycle until radiographic progression. After a 21 day washout period, Enzalutamide therapy given by mouth at 160 mg once daily will be taken for a maximum of 6 cycles while on study.
|
JHUH, SMH | 0 |
Phase II Trial of Radium-223 in Biochemically Recurrent Prostate Cancer
read more
Some men who have been treated for localized prostate cancer with surgery or radiation still show signs of the disease in their blood. This is called biochemically recurrent prostate cancer. Radium-223 is a small molecule. It uses radiation to kill cancer cells and improves survival in advanced prostate cancer. Researchers want to see if it can treat prostate cancer and induced immune changes earlier in the disease when the cancer is only detectable by prostate specific antigen (PSA) in the blood.
Androgen deprivation therapy (ADT) and surveillance are treatment options for prostate cancer patients with biochemical progression after localized therapy with either definitive radiation or surgery (biochemically recurrent prostate cancer or BRPC). A primary goal in these patients is to prevent morbidity from their cancer that results from disease progression and metastatic disease on conventional imaging.
Radium-223 has demonstrated the ability to improve survival in men with symptomatic metastatic castration resistant prostate cancer (mCRPC) with a manageable toxicity profile, particularly in patients who have not yet received docetaxel.
Radiation, even at low doses can impact immune recognition and immune cell killing of cancer cells. Recent findings suggest that radium-223 increase the killing of prostate cancer cells.
Radium-223 may present an alternative option for patients with BRPC that is not associated with substantial toxicity (as seen with ADT) and may have a lasting effect due to its potential effect on the immune system and/or the bone microenvironment.
This study has 1 treatment arm:
Treatment: All patients will receive radium-223 treatment once every 4 weeks for up to 6 cycles. 18F-NaF PET scans will be used to assess response in bone.
|
NCI | 0 |
A Phase 1/2 Study of Combination Olaparib and Radium-223 in Men With Metastatic Castration-Resistant Prostate Cancer With Bone Metastases (COMRADE)
read more
This trial studies the best dose and side effects of olaparib (a type of targeted therapy) and how well it works with radium Ra 223 dichloride (Xofigo, a type of radiation therapy) in treating patients with castration-resistant prostate cancer that has spread to the bone and other places in the body (metastatic). PARPs are proteins that help repair DNA mutations. PARP inhibitors, such as olaparib, can keep PARP from working, so tumor cells can't repair themselves, and they may stop growing. Radioactive drugs, such as radium Ra 223 dichloride, may carry radiation directly to tumor cells and not harm normal cells. Giving olaparib and radium Ra 223 dichloride may help treat patients with castration-resistant prostate cancer.
This study has 2 arms:
Arm A: radium Ra 223 dichloride plus olaparib
Patients receive radium Ra 223 dichloride intravenously (IV) over 1 minute on day 1. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive olaparib by mouth (PO) twice daily on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Arm B: radium Ra 223 dichloride alone
Patients receive radium Ra 223 dichloride as in Arm A. Patients with radiographic progression may crossover to Arm A. If patients have already completed all 6 infusions of radium, they will receive olaparib alone. If they have not yet completed all 6 radium-223 infusion, they will continue radium-223 infusion until completion and receive concurrent treatment with olaparib.
|
UMD | 0 |
Evaluation of local response of CaP to irradiation using multiparametric MRI & MR guided biopsies (NCI 13-c-0119)
read more
This study uses multiparametric MRI-guided and MR-guided biopsies as tools to evaluate response to local radiation therapy. Study subjects include men who have not received any prior treatment but are about to undergo radiation therapy and men whose cancer is progressing after initial radiation therapy. The goal is to use the imaging studies and the genetic information from the biopsies to draw conclusions on how they relate to the efficacy of radiation and radiation resistance. All participants will receive an initial multiparametric MRI and a tissue biopsy. Men who are scheduled for radiation therapy will undergo that therapy. Six months following completion of radiation, they will complete another MRI and additional blood tests. |
NCI | 0 |
A Phase II Study of Neoadjuvant Androgen Deprivation Therapy Combined With Enzalutamide and Abiraterone Using Multiparametric MRI and 18F-DCFPyL-PET/CT in Newly Diagnosed Prostate Cancer
read more
Prostate cancer is a common cancer among men. There are several ways to treat it, including hormone blocking drugs, radiation therapy, and surgery. Researchers want to combine abiraterone (a type of hormonal therapy) and enzalutamide (a type of hormonal therapy) to see if there is a better way to treat prostate cancer. They also want to study a new radiotracer called 18F-DCFPyL, with the help of a scan called positron emission tomography/computed tomography (PET/CT) to see if there is a better way to detect prostate cancer.
Most men diagnosed with prostate cancer will present with intermediate or high-risk disease, and many develop castrate resistant prostate cancer (CRPC) as curative strategies are often unsuccessful. Treatment options typically involve a radical prostatectomy (RP) or radiation therapy (RT) in combination with androgen deprivation therapy (ADT, hormonal therapy).
PET imaging based on prostate specific membrane antigen (PSMA), including use of the radiotracer DCFPyL, which binds PSMA, has emerged as a sensitive modality to detect localized and metastatic prostate cancer.
It is unknown how androgen-targeted therapy affects expression of the androgen- regulated PSMA gene, FOLH1, and 18F -DCFPyL-PET/CT sensitivity; and, the correlation between response on 18F -DCFPyL-PET/CT imaging and clinical response needs further evaluation.
The use of highly effective androgen pathway inhibitors enzalutamide and abiraterone offers an opportunity to understand the characteristics of 18F -DCFPyL-PET imaging during treatment while potentially improving the cure rate of men with potentially lethal localized prostate cancer.
All participants will receive:
Drug: Goserelin will be administered by sub-cutaneous injection (SC) at 10.8 mg once every 12 weeks for 6 months
Drug: Enzalutamide will be taken orally (PO) at 160mg once daily for 6 months
Drug: Abiraterone will be taken orally at 1000 mg once daily for 6 months
Drug: Prednisone will be taken orally at 5mg twice a day for each dose, or 10 mg once a day.
Scans: scans with 18F-DCFPyL will be performed after 2 and 6 months of treatment
Procedure: Prostate tumor biopsy samples for research analyses will be taken at baseline and after 2 month scans are performed
Procedure: Radical prostatectomy to be determined with your treating physician
|
NCI | 0 |
Bicalutamide Implants (Biolen) With Radiation Therapy in Patients With Localized Prostate Cancer
read more
This study will be undertaken to evaluate the feasibility of replacing systemic Androgen Deprivation Therapy (ADT, a type of hormonal therapy) with targeted local delivery of an anti-androgen agent alone in patients in whom ADT + radiation therapy is indicated for the treatment of localized prostate cancer.
This study has 1 treatment arm:
Biolen (bicalutamide, a type of hormonal therapy) + Radiation Therapy
Localized single delivery of the Biolen implant (polymer + bicalutamide) with stereotactic body radiation therapy
|
NCI | 0 |
CASPAR - A Phase III Trial of Enzalutamide and Rucaparib as a Novel Therapy in First-Line Metastatic Castration-Resistant Prostate Cancer
read more
This randomized, placebo-controlled phase III trial is evaluating the benefit of rucaparib (a PARP inhibitor, a type of targeted therapy) and enzalutamide (Xtandi, a type of hormonal therapy) combination therapy versus enzalutamide alone for the treatment of men with prostate cancer that has spread to other places in the body (metastatic) and has become resistant to testosterone-deprivation therapy (castration-resistant). Enzalutamide helps fight prostate cancer by blocking the use of testosterone by the tumor cells for growth. PARP inhibitors, such as rucaparib, fight prostate cancer by prevent tumor cells from repairing their DNA. Giving enzalutamide and rucaparib may make patients live longer or prevent their cancer from growing or spreading for a longer time, or both. It may also help doctors learn if a mutation in any of the DNA repair genes is helpful to decide which treatment is best for the patient.
This study has 2 arms:
Arm A: Enzalutamide plus rucaparib
Patients receive enzalutamide by mouth (PO) once daily (QD) and rucaparib PO twice daily (BID). Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Arm B: Enzalutamide plus placebo
Patients receive enzalutamide PO QD and placebo PO BID. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
|
GWU, VCU, WHC | 0 |
Relugolix Versus Leuprolide in Patients With Prostate Cancer: A Randomized, Open-Label Study to Assess Major Adverse Cardiovascular Events (REPLACE-CV)
read more
This is a randomized study to evaluate the risk of major adverse cardiovascular events (MACE) for relugolix (a type of hormonal therapy) compared with leuprolide acetate (a type of hormonal therapy). This study will collect clinical and cardiovascular risk factor data on patients ages 18 and older who are receiving relugolix or leuprolide acetate for their prostate cancer or in addition to radiation therapy, with a treatment plan to be on androgen deprivation therapy (ADT) for at least one year.
This study has 2 arms:
Arm A: Relugolix
Oral (by mouth, PO) relugolix 120 mg once daily with a loading dose of 360 mg on Day 1.
Arm B: Leuprolide Acetate
Subcutaneous or intramuscular injection of leuprolide acetate 22.5 mg every 3 months or 45 mg every 6 months.
|
WHC | 0 |
A Study of Prospective Monitoring of Subjects With Biochemically Recurrent Prostate Cancer Using 18F-DCFPyL
read more
Prostate cancer is the second leading cause of cancer-related death in American men. The disease recurs in up to 50,000 men each year after their early-stage disease was treated; however, at this stage, imaging scans are often unable to find the disease in the body. In this natural history study, researchers want to find out if a new radiotracer (18F-DCFPyL) injected before positron emission tomography (PET) imaging can help identify sites in the body with cancer.
The objective of this study is to learn more about how 18F-DCFPyL PET/CT scans detect change over time in men with recurrent prostate cancer.
There is no treatment given as part of this study.
Participants will be screened with blood tests. They will also have a bone scan and a computed tomography (CT) scans of the chest, abdomen, and pelvis.
Participants will have an initial study visit. They will have a physical exam and blood tests. They will have a PET/CT scan with 18F-DCFPyL. The radiotracer will be injected into a vein; this will take about 20 seconds. The PET/CT scan will be done 1 to 2 hours later. Participants will lie still on a scanner table while a machine captures images of their body. The scan will take 45 minutes.
Participants will return for blood tests every 3 months.
Participants will return for additional scans with 18F-DCFPyL on this schedule:
Once a year if their previous scan was negative for prostate cancer.
Every 6 months if their previous scan was positive for prostate cancer.
Participants may be in the study up to 5 years.
|
NCI | 0 |
Phase II Trial of 18F-DCFPyL Imaging as a Method to Assess Treatment Response to Stereotactic Body Radiation Therapy
read more
Phase II Trial of 18F-DCFPyL Imaging as a Method to Assess Treatment Response to Stereotactic Body Radiation Therapy
Identifying medium- and high-risk prostate cancer early may allow for treatments to work. But identification can be hard. Researchers want to see if a radiotracer used during PET scans can help.
The purpose of this study is to test how an imaging agent called 18F-DCFPyL detects response to standard prostate cancer treatment.
This study has 1 treatment arm:
Participants will have baseline MRI and PET/CT scans. For the MRI, they may get a contrast agent by IV (intravenous) injection. For the PET/CT scan, they will get an IV injection of 18FDCFPyL. About 1 to 2 hours later, they will get the PET/CT scan. During the scans, participants will lie on their back and remain still for 45 minutes to 1 hour. These scans will be repeated at different points during the study.
Participants will get SBRT (stereotactic body radiation therapy) with or without ADT (androgen deprivation therapy, a type of hormonal therapy).
18F-DCFPyL imaging will be performed at baseline, 8 weeks after ADT initiation, 6 months post SBRT and at recurrence.
|
NCI | 0 |
Randomized Trial Assessing Induction of Double Strand Breaks With Androgen Receptor Partial Agonist in Patients on Androgen Suppression
read more
This study will assess the effectiveness of single pulsed-dose flutamide (a type of anti-androgen or hormonal therapy) in creating double strand breaks (changes to the prostate cancer tumor cells) in prostate cancer within patients receiving central androgen suppression (hormonal therapy) and brachytherapy (radiation therapy).
This study has 2 arms:
Arm A Experimental: Flutamide
A single dose of flutamide 50mg taken by mouth (orally) once prior to brachytherapy and prostatic biopsy.
Arm B: Placebo
A single dose of placebo taken by mouth (orally) once prior to brachytherapy and prostatic biopsy.
|
JHUH | 0 |
Phase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer
read more
This phase III trial studies how well standard systemic therapy with or without definitive treatment (prostate removal surgery or radiation therapy) works in treating participants with prostate cancer that has spread to other places in the body. The addition of prostate removal surgery or radiation therapy to standard systemic therapy for prostate cancer may lower the chance of the cancer growing or spreading.
INDUCTION (all participants): Participants receive 1 of 6 acceptable forms of standard systemic therapy (SST) for 22-28 weeks. The decision of which of the 6 possible options (listed here) will be decided with your doctor.
1. Participants undergo a bilateral orchiectomy.
2. Participants receive goserelin acetate (a type of hormonal therapy) subcutaneously (SC) every 28 days or 12 weeks OR, histrelin acetate (another type of hormonal therapy) SC every 12 months OR, leuprolide acetate (another type of hormonal therapy) SC or intramuscularly (IM) every 1, 3, 4, or 6 months OR, triptorelin (another type of hormonal therapy) every 1, 3, or 6 months.
3. Participants receive goserelin acetate SC every 28 days or 12 weeks OR, histrelin acetate SC every 12 months OR, leuprolide acetate SC or IM every 1, 3, 4, or 6 months OR, triptorelin every 1, 3, or 6 months. Participants also receive nilutamide (a type of hormonal therapy) orally (PO) daily OR, flutamide (another type of hormonal therapy) PO every 8 hours OR, bicalutamide (another type of hormonal therapy) PO daily.
4. Participants receive degarelix (a type of hormonal therapy) by injection for 2 doses and then every 28 days.
5. Participants receive nilutamide PO daily OR, flutamide PO every 8 hours, OR bicalutamide PO daily. Participants also receive docetaxel (Taxotere, a type of chemotherapy) intravenously (IV) over 1 hour every 3 weeks with or without prednisone (a type of steroid) PO every 12 hours.
6. Participants receive nilutamide PO daily OR, flutamide PO every 8 hours, OR bicalutamide PO daily. Participants also receive abiraterone (a type of hormonal therapy) PO daily or prednisone PO every 12 hours.
After completion of 22-28 weeks of SST, participants are then randomized to 1 of 2 arms:
ARM I: Participants receive 1 acceptable form of SST as in Induction (above) except for treatment with docetaxel and prednisone.
|
GWU, VCU | 0 |
Biomarker Study to Determine Frequency of DNA-repair Defects in Men With Metastatic Prostate Cancer
read more
The purpose of this study is to evaluate the prevalence of 4 or more DNA-repair defects in a population of men with metastatic Prostate Cancer (PC) and to use the results reported to assess eligibility for niraparib (Zejula, a type of targeted therapy, a PARP inhibitor) treatment studies.
Participants will be consented to saliva, blood, or existing tumor tissue sample testing for the presence or absence of DNA repair defects.
This is NOT a treatment study.
|
VCS | 0 |
A Phase 1b/2, Open-Label, Randomized Platform Study Evaluating the Efficacy and Safety of AB928-Based Treatment Combinations in Patients With Metastatic Castrate Resistant Prostate Cancer (J2077)
read more
This is a Phase 1b/2, open-label, multicenter platform trial to evaluate the antitumor activity and safety of etrumadenant (AB928, a type of targeted therapy)-based combination therapy in participants with metastatic castrate resistant prostate cancer (mCRPC).
This study has multiple arms with 2 standard of care comparator arms:
Arm A: Etrumadenant + zimberelimab + enzalutamide
Participants will receive oral etrumadenant in combination with intravenous (IV) zimberelimab (a type of immunotherapy) and standard oral enzalutamide (Xtandi, a type of hormonal therapy).
Comparator: Enzalutamide
Participants will receive standard of care oral enzalutamide.
Arm B: Etrumadenant + zimberelimab + docetaxel
Participants will receive oral etrumadenant in combination with IV zimberelimab and standard IV docetaxel (Taxotere, a type of chemotherapy)
Comparator: Docetaxel
Participants will receive standard of care dose of IV docetaxel.
Arm C: Etrumadenant + zimberelimab
Oral etrumadenant in combination IV zimberelimab.
Arm D: Etrumadenant + zimberelimab + AB680
Participants will receive oral etrumadenant in combination with IV zimberelimab and IV AB680 (a type of targeted therapy).
Arm E: Etrumadenant + AB680
Participants will receive oral etrumadenant in combination with IV AB680.
|
SMH | 0 |
A Phase III Double-Blind, Randomised, Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Abiraterone Versus Placebo + Abiraterone as Treatment for Patients With DeNovo Metastatic Hormone-Sensitive Prostate Cancer Characterised by PTEN Deficiency.
read more
This study will assess the effectiveness and safety of capivasertib (a type of targeted therapy) plus abiraterone (Zytiga, a type of hormonal therapy) plus androgen deprivation therapy (ADT) versus placebo plus abiraterone plus ADT in participants with metastatic hormone sensitive prostate cancer (mHSPC) whose tumors are characterized by PTEN deficiency. The intention of the study is to demonstrate that in participants with mHSPC, the combination of capivasertib plus abiraterone plus ADT is superior to placebo plus abiraterone plus ADT in participants with mHSPC characterized by PTEN deficiency.
The study has 2 treatment arms:
Arm A: Capivasertib + Abiraterone
Capivasertib 400 mg (2 tablets) by mouth (orally or PO) twice daily (BID) given on an intermittent weekly dosing schedule. Patients will be dosed on Days 1 to 4 in each week of a 28-day treatment cycle. Number of Cycles: until disease progression or unacceptable toxicity develops PLUS Abiraterone Acetate administered by mouth (orally or PO) as tablets at a dosage of 1000 mg once daily. Administered continuously until criteria for discontinuation are met.
Arm B: Placebo + Abiraterone
Placebo will be matched to capivasertib appearance (2 tablets) by mouth (orally or PO) twice daily (BID) given on an intermittent weekly dosing schedule. Patients will be dosed on Days 1 to 4 in each week of a 28-day treatment cycle. Number of Cycles: until disease progression or unacceptable toxicity develops PLUS Abiraterone Acetate administered by mouth (orally or PO) as tablets at a dosage of 1000 mg once daily. Administered continuously until criteria for discontinuation are met.
|
UMD | 0 |
A Phase 2 Multicohort Study of Nivolumab in Combination With Docetaxel and Androgen Deprivation Therapy in Metastatic Hormone Sensitive Prostate Cancer Patients With DNA Damage Repair Defects or Inflamed Tumors (J19144)
read more
This research study is studying a combination of hormonal therapy, chemotherapy, and immunotherapy as a possible treatment for metastatic hormone-sensitive prostate cancer.
The names of the study drugs involved in this study are:
Androgen deprivation therapy (ADT, hormonal therapy) with a drug of your physician's choice. This may include leuprolide (Lupron), goserelin acetate (Zoladex), or degarelix (Firmagon).
Docetaxel (Taxotere, a type of chemotherapy)
Nivolumab (Opdivo, a type of immunotherapy).
The combination of ADT, also called hormonal therapy, with docetaxel chemotherapy and nivolumab immunotherapy is considered investigational. ADT cuts off the supply of testosterone and is the standard of care for hormone sensitive prostate cancer. The addition of docetaxel chemotherapy has been found to prolong life for prostate cancer patients starting hormonal therapy for the first time for metastatic disease, who also have a large volume of cancer.
Another anti-cancer treatment modality is called immunotherapy. The immune system can kill cells that are recognized as different or dangerous, such as infected cells and cancer cells. Nivolumab is an antibody (a type of human protein) that work to stimulate the body's immune system to recognize and fight cancer cells.
Hormonal therapy and chemotherapy may make cancer cells more recognizable to the immune system and make cancer cells more susceptible to immunotherapy.
The goal of this study is to examine the activity and safety of hormonal therapy combined with docetaxel chemotherapy and nivolumab immunotherapy for hormone sensitive prostate cancer.
Treatment – all patients will receive the same treatment of ADT combined with docetaxel chemotherapy and nivolumab immunotherapy.
Androgen Deprivation Therapy: Given per standard care for duration of study.
Nivolumab: Given once every 3 weeks for cycle 1-6 intravenously (IV) in clinic, and then every 4 weeks during subsequent cycles, at a predetermined dosage.
Docetaxel: Given once every 3 weeks intravenously (IV) in clinic at a pre-determined dosage for cycle 1-6.
|
JHUH | 0 |
Natural History Study of Men at High Genetic Risk for Prostate Cancer
read more
Research studies have shown that genetic changes and family history may increase a man s risk for prostate cancer. Researchers want to follow the prostate health of men who have specific genetic changes associated with prostate cancer to help them learn more about which men are at higher risk for prostate cancer.
Prostate cancer is the most common malignancy and the second leading cause of cancer-related deaths in American men.
Prostate cancer has substantial inherited predisposition and certain genetic variants that
are associated with an increased risk of prostate cancer.
An evolving approach to prostate cancer screening is to target populations at risk of
developing prostate cancer based on their genetic predisposition.
The objective of this study is to study men with specific genetic changes and determine who is at higher risk for getting prostate cancer, and to study if certain genetic changes and family history can be used to help prevent or treat prostate cancer.
There is NO treatment given in this study.
Participants will undergo sampling of blood for prostate-specific antigen (PSA) and digital
rectal exams. Based on these results and age, patients will be considered for biopsy
and/or continued monitoring. Participants will undergo a baseline MRI evaluation with follow-up scans every 2 years as clinically indicated.
Following initial evaluation, participants will be followed as clinically indicated, usually
at 12 month intervals, to determine their PSA level, prostate cancer treatment (if relevant)
and/or disease/survival status until death.
|
NCI | 0 |
A Phase II Study Evaluating T-Cell Clonality After Stereotactic Body Radiation Therapy Alone and in Combination With the Immunocytokine M9241 in Localized High and Intermediate Risk Prostate Cancer Treated With Androgen Deprivation Therapy
read more
Prostate cancer is often treated with radiation and ADT (ADT is androgen deprivation therapy, a type of hormonal therapy). Up to 30% of these cancers recur within 5 years of treatment. Researchers want to see if a new drug (M9241, a type of hormonal therapy) can help the immune system to fight prostate cancer.
There is a growing body of evidence suggesting that stereotactic body radiation therapy (SBRT, a type of radiation treatment), which delivers highly conformal high-dose radiation, can promote anti-tumor immune responses both locally and systemically as well as synergize (enhance the effect) with immune checkpoint inhibitors and other forms of immunotherapy.
The objectives of the study are to find what doses of M9241 are safe in people who are treated for prostate cancer, to see what effects M9241 has on the immune system and to evaluate whether immunocytokines (like M9241) can synergize with standard radiation + ADT therapy in prostate cancer.
This study has 2 treatment arms:
Arm A: Radiation only with Stereotactic Body Radiation Therapy (SBRT)
SBRT to the prostate will be delivered in 5 fractions of radiation each of 7.25-8.0 Gy, every other day over the course of 10 business days (2-3 weeks). The total dose will be 36.25-40 Gy.
Arm B: Radiation + M9241
SBRT to the prostate will be delivered in 5 fractions of radiation each of 7.25-8.0 Gy, every other day over the course of 10 business days (2-3 weeks). The total dose will be 36.25-40 Gy PLUS M9241 (dose level to be provided by treatment team) given by subcutaneous (SQ or SC) injection once every 4 weeks for 3 doses total. The first M9241 dose will be given 4 weeks after radiation has ended.
|
NCI | 0 |
The Impact of DNA Repair Pathway Alterations Identified by Circulating Tumor DNA on Sensitivity to Radium-223 in Bone Metastatic Castration-Resistant Prostate Cancer (J12173)
read more
This phase II study investigates how well radium-223 (a type of radiation therapy) works in treating patients with castration-resistant prostate cancer (CRPC) than has spread to the bones (bone metastases).
Prostate cancer is the most common cancer in men and the second leading cause of cancer death. Furthermore, many men with notably advanced disease have been found to have abnormalities in DNA repair. The purpose of this research is to study the role of a DNA repair pathway in prostate cancer, specifically in response to administration of radium-223, an FDA-approved drug known to cause DNA damage to cancerous cells. Understanding how defects in the DNA repair pathway affects radium-223 treatment of prostate, may help doctors help plan effective treatment in future patients.
All participants will receive treatment. Patients receive standard of care radium Ra 223 dichloride (Alpharadin) given by intravenous (IV) bolus every 4 weeks for up to 6 cycles. Patients undergo collection of blood every 1-3 months during radium Ra 223 dichloride treatment.
|
JHUH | 0 |
Nivolumab as a Non-Castrating Therapy for MMR-deficient and CDK12- Altered Prostate Cancer With PSA Recurrence After Local Therapy (J1933)
read more
MMR-deficient cancers of any type appear to be very sensitive to PD-1 blockade with pembrolizumab (Keytruda, a type of immunotherapy), and similar data are also beginning to emerge for nivolumab (Opdivo, a type of immunotherapy) and other immune checkpoint inhibitors.
For men who previously received definitive treatment (prostatectomy and/or radiation therapy) for prostate cancer and subsequently develop detectable prostate specific antigen (PSA) levels, the clinical state is known as biochemically recurrent prostate cancer. The current standard of care treatment for patients with biochemically recurrent prostate cancer is either surveillance or androgen deprivation therapy (ADT, hormonal therapy). ADT has not been shown to provide a survival benefit in this setting, and the decision to initiate ADT will depend on patient preference and perceived risks of the disease. A non-hormonal therapy such as nivolumab would provide an alternative to ADT in patients with biomarker selected (i.e. genetic markers like dMMR, MSI-H, high TMB, or CDK12-altered) biochemically recurrent prostate cancer.
Treatment – this study has 1 arm.
Nivolumab is given at 480mg intravenously (IV) once every 4 weeks in clinic.
|
JHUH | 0 |
Phase III Study of PET-Directed Local or Systemic Therapy Intensification in Prostate Cancer Patients With Post-Prostatectomy Biochemical Recurrence
read more
This phase III trial compares the addition of apalutamide (a type of hormonal therapy), with or without targeted radiation therapy, to standard of care treatment versus standard of care treatment alone in patients with prostate cancer biochemical recurrence (a rise in the blood level of prostate-specific antigen [PSA] after treatment with surgery or radiation). Diagnostic procedures, such as positron emission tomography/computed tomography (PET/CT), may help doctors look for cancer that has spread to the pelvis. Androgens can cause the growth of prostate cancer cells. Apalutamide may help fight prostate cancer by blocking the use of androgens by the tumor cells. Targeted radiation therapy uses high energy rays to kill tumor cells and shrink tumors that have spread. This trial may help doctors determine if using PET/CT results to deliver more tailored treatment (i.e., adding apalutamide, with or without targeted radiation therapy, to standard of care treatment) works better than standard of care treatment alone in patients with biochemical recurrence of prostate cancer.
This study has 4 treatment arms:
Arm A: PET scan plus standard of care radiation and hormonal therapy
Arm B: PET scan, standard of care radiation and hormonal therapy PLUS apalutamide by mouth (PO) once daily (QD) for 6 months in the absence of disease progression or unacceptable toxicity.
Arm C: PET scan, standard of care radiation and hormonal therapy PLUS apalutamide by mouth (PO) once daily (QD) for 6 months in the absence of disease progression or unacceptable toxicity. Patients randomized to this arm will receive an additional PET scan at 12 months (or at second rise in PSA).
Arm D: PET scan, standard of care radiation and hormonal therapy PLUS apalutamide by mouth (PO) once daily (QD) for 6 months in the absence of disease progression or unacceptable toxicity. Patients randomized to this arm also receive targeted radiation therapy over 3-5 fractions in the absence of disease progression or unacceptable toxicity.
|
SMH | 0 |
Phase III Trial of Docetaxel vs. Docetaxel and Radium-223 for Metastatic Castration-Resistant Prostate Cancer (mCRPC)
read more
The purpose of this study is to compare any good and bad effects of using radium-223 (a type of radiation therapy) along with docetaxel (a type of chemotherapy) treatment versus using docetaxel alone.
The study has 2 arms:
Arm 1: Docetaxel
Docetaxel 75 mg/m2 will be administered intravenously (IV) every three weeks for 10 doses. Prednisone will be given at a dose of 5mg orally twice daily.
Arm 2: Docetaxel with Radium-223
Docetaxel 60 mg/m2 will be administered IV every 3 weeks for 10 doses. Radium-223 will be administered at 55 kBq/kg, 6 injections at 6 weeks intervals.
|
UMD | 0 |
Phase I/II Study of M9241 with Docetaxel and Abiraterone in Adults with Metastatic Castration Sensitive and M9241 with Docetaxel in Castration Resistant Prostate Cancer.
read more
Metastatic castration sensitive and castration resistant prostate cancer (mCSPC and mCRPC) are prostate cancers that have spread to other parts of the body. Use of the drug docetaxel (Taxotere, a type of chemotherapy) with androgen deprivation therapy can improve survival for men with mCSPC. Researchers want to see if combining this treatment with other drugs can help delay the time it takes for mCSPC and mCRPC to get worse.
The objective of this study is to determine if giving docetaxel with M7824 (Bintrafusp Alfa, a type of immunotherapy) and M9241 (NHS-IL12, a type of immunotherapy) is safe and effective for men with prostate cancer.
This study has 2 treatment arms:
Arm A: Docetaxel plus M9241 dose escalation with optional prednisone (a type of steroid) and ADT (androgen deprivation therapy, a type of hormonal therapy) as part of SOC (standard of care).
Docetaxel 75mg/m^2 will be administered intravenously (IV) once every 21 days (a 3-week cycle) for up to 6 cycles in mCSPC and until progression or unacceptable toxicity in mCRPC.
M9241 at escalating doses will be administered as a subcutaneous (SC or SQ) injection once every three weeks.
Prednisone and ADT will be given per standard of care (SOC)
Arm B: Docetaxel plus M9241 plus M7824 with optional prednisone and ADT as part of SOC.
Docetaxel and M9241 given the same as above plus M7824 (2400 mg) will be administered as a 1 hour intravenous (IV) infusion once every three weeks.
Prednisone and ADT will be given per standard of care (SOC)
|
NCI | 0 |
Prostate Cancer Outcomes: An International Registry to Improve Outcomes in Men With Advanced Prostate Cancer (IRONMAN) (J1726)
read more
The intent of this study is to establish the International Registry to Improve Outcomes in Men with Advanced Prostate Cancer (IRONMAN). The goal is to establish a population-based registry and recruit patients across academic (affiliated with a teaching hospital or medical school) and community practices from Australia, Brazil, Canada, Ireland, Sweden, Switzerland, the United Kingdom (UK), and the US. This cohort study will facilitate a better understanding of the variation in care and treatment of advanced prostate cancer across countries and across academic and community based practices.
Detailed data will be collected from patients at study enrollment and then during follow-up, for a minimum of three years. Patients will be followed for overall survival, clinically significant adverse events, comorbidities (other diseases or illnesses that may arise), changes in cancer treatments, and PROMs (a type of quality of life questionnaire).
PROMs questionnaires will be collected at enrollment, every three months for the first and second year, then every six months.
As such, this registry will help identify the treatment sequences or combinations that optimize overall survival and PROMs (quality of life). By collecting blood at enrollment, time of first change in treatment and/or one year follow-up, this registry will further identify and validate molecular phenotypes (differences based on specific cells in the blood) of disease that predict response and resistance to specific therapeutics. Additionally, every effort will be made to collect blood specimen at each subsequent change in treatment. When feasible, existing tumor tissue may be collected for correlation with described blood based studies. All samples will be used for future research. This cohort study will provide the research community with a unique biorepository (collected of blood and tumor tissue) to identify biomarkers (specific cells in the blood or tumor tissue) of treatment response and resistance.
|
JHUH | 0 |
Parallel Phase III Randomized Trials of Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification and Intensification Clinical Trial Evaluation (GUIDANCE)
read more
This phase III trial uses the Decipher risk score to guide intensification (for higher Decipher gene risk) or de-intensification (for low Decipher gene risk) of treatment to better match therapies to an individual patient's cancer aggressiveness. The Decipher risk score evaluates a prostate cancer tumor for its potential for spreading. In patients with low risk scores, this trial compares radiation therapy alone to the usual treatment of radiation therapy and hormone therapy (androgen deprivation therapy or ADT). Radiation therapy uses high energy x-rays or particles to kill tumor cells and shrink tumors. Androgen deprivation therapy blocks the production or interferes with the action of male sex hormones such as testosterone, which plays a role in prostate cancer development. Giving radiation treatment alone may be the same as the usual approach in controlling the cancer and preventing it from spreading, while avoiding the side effects associated with hormonal therapy.
In patients with higher Decipher gene risk, this trial compares the addition of darolutamide (Nubeqa) to usual treatment radiation therapy and hormone therapy, to usual treatment. Darolutamide blocks the actions of the androgens (like testosterone) in the tumor cells and in the body. The addition of darolutamide to the usual treatment may better control the cancer and prevent it from spreading.
This study has 3 arms:
Arm A: Radiation alone
Patients undergo RT using a recognized regimen (2-3 days a week or 5 days a week for 2-11 weeks) in the absence of disease progression or unacceptable toxicity.
Arm B: Radiation + ADT
Patients undergo RT as Arm A. Patients also receive ADT consisting of leuprolide, goserelin, buserelin, histrelin, triptorelin, degarelix, or relugolix at the discretion of the treating physician, for 6 months in the absence of disease progression or unacceptable toxicity. Patients may also receive bicalutamide or flutamide for 0, 30 or 180 days.
Arm C: Radiation + ADT + darolutamide
Patients receive RT and ADT as in Arm II. Patients also receive darolutamide PO BID on days 1-90. Treatment repeats every 90 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity.
|
VCU | 0 |
Highly Conformal, Hypofractionated, Focally Dose Escalated Post-Prostatectomy Radiotherapy
read more
Sometimes prostate cancer comes back after a person’s prostate is removed. In this case,
radiation is a common treatment. Radiation kills prostate cancer cells. It can be very effective. It
is usually given in short doses almost every day for 6 or 7 weeks. Researchers want to see if a
shorter schedule can be equally as effective. They want to see if a shorter schedule causes the
same or fewer side effects. Usually, radiation is used to treat the entire area where the prostate
was before surgery. In some patients, an area of tumor can be seen on scans. Researchers are
also trying to see if they can give a lower dose to the area usually treated with radiation (the
entire prostate bed) if the full dose is given to the tumor seen on scans.
There will be two arms on this study:
Arm 1 - Dose to prostate bed with integrated boost
Radiation will be delivered to an escalated dose to areas of recurrent prostate cancer identified
on imaging and a reduced dose will be delivered to the entire prostate bed.
Arm 2 - Dose to prostate bed
Radiation will be delivered to the prostate bed only (this is considered standard of care). |
NCI | 0 |
Evaluation of 18F-DCFPyL PSMA- Versus 18F-NaF-PET Imaging for Detection of Metastatic Prostate Cancer
read more
Prostate cancer is the second leading cause of cancer deaths in American men. Few options exist to create images of this type of cancer. Researchers think an experimental radiotracer called 18F-DCFPyL could find sites of cancer in the body.
Participants will have 18F-DCFPyL injected into a vein. About 2 hours later they will have a whole-body Positron Emission Tomography/Computed Tomography (PET/CT). For the scan, participants will lie on their back on the scanner table while it takes pictures of the body. This lasts about 50 minutes.
On another day, participants will have 18F -NaF injected into a vein. About 1 hour later, they will have a whole-body PET/CT.
If the 18F-DCFPyL PET/CT is positive participants will be encouraged to undergo a biopsy of one of the tumors. The biopsy will be taken through a needle put through the skin into the tumor.
Participants will be followed for 1 year. During this time researchers will collect information about their prostate cancer, such as PSA levels and biopsy results.
There is no treatment given on this protocol.
|
NCI | 0 |
Phase II Study of PARP Inhibitor Olaparib and IV Ascorbate in Castration Resistant Prostate Cancer (J21127)
read more
This is a study to evaluate the safety and clinical activity of the combination of olaparib (Lynparza, a type of targeted therapy) and high-dose intravenous (IV) ascorbate (vitamin C, a type of supplement or nutraceutical), as second or later line of therapy, in castration resistant prostate cancer patients with no known DNA repair gene mutations (DDRm). In brief, the primary endpoint is PSA response, defined by a 50% reduction in PSA from baseline . The secondary endpoints are assessing the PSA doubling time (how quickly PSA rises), radiographic (imaging like CT or bone scans) and PSA progression free survival (PFS), safety and tolerability, and measuring overall survival.
This study has one treatment arm: Olaparib and Vitamin C
Olaparib will be administered at 300 mg by mouth (orally, PO), twice daily; ascorbate will be administered at 1 g/kg intravenously (IV) twice weekly at least 24 hours apart, until objective disease progression or unacceptable toxicities or patient withdrawal for other reasons.
|
JHUH | 0 |
Overcoming Drug Resistance in Metastatic Castration-resistant Prostate Cancer With Novel Combination of TGF-β Receptor Inhibitor LY2157299 and Enzalutamide: a Randomized Multi-site Phase II Study (J1557)
read more
The primary objective of this study is to compare the progression free survival (PFS) of patients with metastatic castration-resistant prostate cancer treated with enzalutamide (Xtandi, a type of hormonal or anti-androgen therapy) in combination with LY2157299 (a type of targeted therapy) versus enzalutamide alone. The hypothesis is that patients receiving enzalutamide in combination with LY2157299 will have longer progression free survival than patients receiving enzalutamide alone.
This study has 2 treatment arms:
Arm A: Enzalutamide + LY2157299
Enzalutamide 160mg taken orally (by mouth, PO) once a day on days 1-28 of each cycle PLUS LY2157299 150 mg taken orally twice a day on days 1-14 of each cycle.
Arm B: Enzalutamide alone
Enzalutamide 160mg taken orally (at home) once a day on days 1-28 of each cycle.
|
JHUH, SMH | 0 |
Phase I/II Study of Immunotherapy Combination BN-Brachyury Vaccine, M7824, ALT-803 and Epacadostat (QuEST1).
read more
This is an effectiveness seeking trial, utilizing sequential arms as a means to identify signals of activity for combinations of immunotherapy in metastatic castrate resistant prostate cancer (mCRPC) patients.
PD-1/PD-L1 signaling appears to be a major inhibitor of activated T cell anti-tumor immune responses. The rapid, deep and durable responses seen in various malignancies with PD-1/PD-L1 targeted agents demonstrate that blockade of this axis is key to facilitating immune responses within the tumor microenvironment (TME). Prostate cancer is poorly recognized by T cells. Lack of an immune response is one explanation for the lower response rates (<15%) observed with anti-PD-1/PD-L1 therapies for prostate cancer. Increasing response rates will likely require therapeutic correction of multiple immune deficits by combining immunotherapies.
In treating of mCRPC, we hypothesize that these agents and their effects will be complementary. Tumor-specific T cells generated by vaccine may become more functional in a TME following treatment with M7824 and Epacadostat. ALT-803 can further enhance the activity of these vaccines.
This study has 7 arms (although some B arms are expansions of previous A arms):
Arm 1.1: M7824 + ALT-803
M7824 at 1,200 mg given intravenously (IV) once every 2 weeks
ALT-803 at 10-20 mkg/kg given by subcutaneous injection once every 2 weeks
Arm 2.1A M7824 + BN-Brachyury
M7824 at 1,200 mg given IV once every 2 weeks
MVA-BN-Brachyury given by subcutaneous injection for 2 doses, 2 weeks apart
FPV-Brachyury given by subcutaneous injection 2 weeks after the second dose of MVA- BN-Brachyury, then every 4 weeks until 6 months, then every 3 months for 2 years, then every 6 month.
Arm 2.2A M7824 + BN-Brachyury + ALT-803
M7824 at 1,200 mg given IV once every 2 weeks
ALT-803 at 10-20 mkg/kg given by subcutaneous injection every 2 weeks
MVA-BN-Brachyury given by subcutaneous injection for 2 doses, 2 weeks apart
FPV-Brachyury given by subcutaneous injection 2 weeks after the second dose of MVA- BN-Brachyury, then every 4 weeks until 6 months, then every 3 months for 2 years, then every 6 month.
Arm 2.3A M7824 + BN-Brachyury + ALT-803 + Epacadostat
M7824 at 1,200 mg given IV once every 2 weeks
ALT-803 at 10-20 mkg/kg given by subcutaneous injection every 2 weeks
MVA-BN-Brachyury given by subcutaneous injection for 2 doses, 2 weeks apart
FPV-Brachyury given by subcutaneous injection 2 weeks after the second dose of MVA- BN-Brachyury, then every 4 weeks until 6 months, then every 3 months for 2 years, then every 6 month.
Epacadostat at 100 mg taken orally twice daily (200 mg total)
Arm 2.1B M7824 + BN-Brachyury
M7824 at 1,200 mg given IV once every 2 weeks
MVA-BN-Brachyury given by subcutaneous injection for 2 doses, 2 weeks apart
FPV-Brachyury given by subcutaneous injection 2 weeks after the second dose of MVA- BN-Brachyury, then every 4 weeks until 6 months, then every 3 months for 2 years, then every 6 month.
Arm 2.2B M7824 + BN-Brachyury + ALT-803
M7824 at 1,200 mg given IV once every 2 weeks
ALT-803 at 10-20 mkg/kg given by subcutaneous injection every 2 weeks
MVA-BN-Brachyury given by subcutaneous injection for 2 doses, 2 weeks apart
FPV-Brachyury given by subcutaneous injection 2 weeks after the second dose of MVA- BN-Brachyury, then every 4 weeks until 6 months, then every 3 months for 2 years, then every 6 month.
Arm 2.3B M7824 + BN-Brachyury + ALT-803 + Epacadostat
M7824 at 1,200 mg given IV once every 2 weeks
ALT-803 at 10-20 mkg/kg given by subcutaneous injection every 2 weeks
MVA-BN-Brachyury given by subcutaneous injection for 2 doses, 2 weeks apart
FPV-Brachyury given by subcutaneous injection 2 weeks after the second dose of MVA- BN-Brachyury, then every 4 weeks until 6 months, then every 3 months for 2 years, then every 6 month.
Epacadostat at 100 mg taken orally twice daily (200 mg total)
|
NCI | 0 |
A Phase 1/1b Dose Escalation and Cohort Expansion Study of MGC018 in Combination With Checkpoint Inhibitor in Participants With Advanced Solid Tumors (J2204)
read more
This is a study of vobramitamab duocarmazine (MGC018, a type of targeted therapy) in combination with lorigerlimab (a type of immunotherapy). The study is designed to characterize safety, tolerability, drug activity, and preliminary antitumor activity. Participants with relapsed or refractory, unresectable, locally advanced or metastatic solid tumors including metastatic castration resistant prostate cancer (mCRPC) and renal cell carcinoma (RCC) will be enrolled.
All participants will receive treatment.
Vobramitamab duocarmazine and lorigerlimab will be given intravenously (IV) once every 4 weeks. Dosage level will be provided by the treatment team.
|
JHUH | 0 |
NCT04300855 Participants participating in the study will be randomized 2:1 (2 study agent: 1 placebo) to receive Sunphenon® 90D (405 mg EGCG BID) or placebo.
read more
This randomized double-blinded Phase II clinical trial will evaluate the bioavailability, safety, effectiveness and validate the mechanism by which a standardized formulation of whole Green Tea Catechin, (Sunphenon® 90D, a type of nutritional supplement or neutraceutical) containing 405 mg versus Placebo, administered for 24 months in a cohort of men with low to intermediate grade prostate managed on active surveillance.
This study has 2 arms:
Arm A: Sunphenon® 90D
Participants will be administered a standardized formulation of whole Green Tea Catechin by mouth (PO, orally) twice daily for 24 months. The daily dose of Green Tea Catechin will be taken in divided doses, three capsules in the morning and 3 capsules in the evening, with food (within one hour of eating a substantial meal). On the day of monthly follow-up visit, capsules should be taken within 4 hours of visit and blood draw for required lab work. If the participant is scheduled to come in the afternoon, dose should be taken with lunch that day instead of with dinner for that day.
Arm B: Placebo
Participants will be administered a placebo by mouth twice daily for 24 months. The daily dose of placebo will be taken in divided doses, three capsules in the morning and 3 capsules in the evening, with food (within one hour of eating a substantial meal). On the day of monthly follow-up visit, capsules should be taken within 4 hours of visit and blood draw for required lab work. If the participant is scheduled to come in the afternoon, dose should be taken with lunch that day instead of with dinner for that day.
|
GWU | 0 |
Phase Ib/II Trial of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-365)
read more
The purpose of this study is to assess the safety and efficacy of pembrolizumab (Keytruda or MK-3475, a type of immunotherapy) combination therapy in patients with metastatic castrate resistant prostate cancer (mCRPC). It is thought that combining pembrolizumab with other therapies will be more effective than those therapies alone.
This study has 8 treatment arms:
Arm 1: Pembrolizumab + Olaparib (Lynparza, a type of targeted therapy)
Participants will receive pembrolizumab 200 mg intravenously (IV) on Day 1 of each 3-week dosing cycle (Q3W) and olaparib 400 mg capsules or 300 mg tablets by mouth (PO or orally) twice a day (BID) continuously from Day 1 of Cycle 1. Treatment with pembrolizumab will continue until progression or a maximum of 35 treatment cycles (up to 2 years). Treatment with olaparib will continue until progression. Participants who must discontinue 1 of the 2 drugs in the combination due to adverse events may continue the study with the other combination drug.
Arm 2: Pembrolizumab + Docetaxel (Taxotere, a type of chemotherapy) + Prednisone (a steroid)
Participants will receive pembrolizumab 200 mg IV on Day 1 Q3W, docetaxel IV on Day 1 Q3W, and prednisone 5 mg tablet PO BID continuously from Day 1 of Cycle 1. Participants will only be permitted to receive a maximum of 10 cycles of docetaxel and prednisone. Treatment with pembrolizumab will continue for a maximum of 35 cycles (up to 2 years) or until progression. Participants who must discontinue 1 of the 2 drugs due to adverse events in the combination may continue the study with the other combination drug.
Arm 3: Pembrolizumab + Enzalutamide (Xtandi, a type of hormonal therapy)
Participants will receive pembrolizumab 200 mg IV on Day 1 Q3W and enzalutamide 160 mg PO every day (QD) continuously from Day 1 of Cycle 1. Treatment with pembrolizumab will continue until progression or a maximum of 35 treatment cycles (up to 2 years). Treatment with enzalutamide will continue until progression. Participants who must discontinue 1 of the 2 drugs in the combination due to adverse events may continue the study with the other combination drug.
Arm 4: Pembrolizumab + Abiraterone (Zytiga, a type of hormonal therapy) + Prednisone (a steroid)
Participants will receive pembrolizumab 200 mg IV on Day 1 Q3W, abiraterone acetate 1000 mg PO QD and prednisone 5 mg tablet PO BID continuously from Day 1 of Cycle 1. Treatment with pembrolizumab will continue for a maximum of 35 cycles (up to 2 years) or until progression. Participants who must discontinue 1 of the 2 drugs due to adverse events in the combination may continue the study with the other combination drug.
Arm 5: Pembrolizumab + Lenvatinib (Lenvima, a type of targeted therapy)
Participants will receive pembrolizumab 200 mg IV on Day 1 Q3W, and lenvatinib 20 mg PO QD continuously from Day 1 of Cycle 1. Treatment with pembrolizumab will continue for a maximum of 35 cycles (up to 2 years) or until progression. Participants who must discontinue 1 of the 2 drugs due to adverse events in the combination may continue the study with the other combination drug.
Arm 6: Pembrolizumab + Vibostolimab coformulation (a type of targeted therapy)
Participants with AC mCRPC in Cohort G will receive a coformulation fixed dose combination of 200 mg pembrolizumab and 200 mg vibostolimab (MK-7684) Q3W IV from Day 1 of Cycle 1. Treatment will continue for a maximum of 35 cycles (up to 2 years) or until progression.
Arm 7: Pembrolizumab + Carboplatin + Etoposide
Participants will receive pembrolizumab 200 mg IV on Day 1 Q3W + carboplatin IV on Day 1 Q3W + etoposide IV on Days 1, 2, and 3 Q3W. Treatment with pembrolizumab will continue for a maximum of 35 cycles (up to 2 years) or until progression. Treatment with carboplatin + etoposide will continue for a maximum of 4 cycles (up to 2.8 months). Participants who must discontinue 1 or 2 of the 3 drugs due to adverse events in the combination may continue the study with the other combination drug/drugs.
Arm 8: Carboplatin + Etoposide
Participants will receive carboplatin IV on Day 1 Q3W + etoposide IV on Days 1, 2, and 3 Q3W. Treatment will continue for a maximum of 35 cycles (up to 2 years) or until progression. Treatment with carboplatin + etoposide will continue for a maximum of 4 cycles (up to 2.8 months). Participants who must discontinue 1 of the 2 drugs due to adverse events in the combination may continue the study with the other combination drug.
|
GUH | 0 |
A Phase 2 Study Evaluating Activity of Zenocutuzumab (MCLA-128) in Patients With or Without Molecularly Defined Cancers
read more
This is a Phase II, open-label, 2-arm, multicenter, international study designed to evaluate the effectiveness of zenocutuzumab (a type of targeted therapy) in combination with enzalutamide (Xtandi, a type of hormonal therapy) OR abiraterone (Zytiga, a type of hormonal therapy) in patients with metastatic castration resistant prostate cancer (mCRPC).
This study has one arm for mCRPC:
Zenocutuzumab + Enzalutamide OR Abiraterone
Participants will receive intravenous (IV) infusion of 750 mg of zenocutuzumab once every 2 weeks in combination with the AR targeting (hormonal therapy) agent they experienced disease progression on prior to study entry:
Enzalutamide 160 mg orally (by mouth, PO) once daily OR abiraterone 1000 mg orally once daily with prednisone 5 mg orally twice daily.
|
CCBD | 0 |
A Phase 1/2 Open-Label, Dose-Escalation and Cohort Expansion Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ARV-766 in Patients With Metastatic Castration-Resistant Prostate Cancer
read more
A Phase 1/2 study to evaluate the safety and effectiveness of ARV-766 (a type of targeted therapy) given by mouth in men with metastatic castration-resistant prostate cancer who have progressed on prior approved systemic therapies.
All patients will receive treatment with ARV-766 taken orally (by mouth, po) once or twice daily for 28 day cycles. Dose level and dosing schedule will be provided by the treatment team.
|
VCS | 0 |
A Phase 2, Randomized, Open-label, Study of Two Dose Levels of Obramitamab Duocarmazine in Participants With Metastatic Castration-resistant Prostate Cancer
read more
This study is a randomized, open-label, Phase 2 study. The study will enroll participants with metastatic castration-resistant prostate cancer (mCRPC) previously treated with one prior androgen receptor axis-targeted therapy (ARAT, a type of hormonal therapy). ARAT includes abiraterone, enzalutamide, or apalutamide. Participants may have received up to 1 prior taxane-containing regimen, but no other chemotherapy agents.
The study will assess effectiveness and tolerability of vobramitamab duocarmazine (a type of targeted therapy) at two different dose levels.
All patients will receive treatment with vobramitamab duocarmazine at either 2.0 or 2.7 mg/kg given intravenously (IV) one every 4 weeks.
|
VCS | 0 |
A Phase III Double Blinded Study of Early Intervention After RADICAl ProstaTEctomy With Androgen Deprivation Therapy With or Without Darolutamide vs. Placebo in Men at Highest Risk of Prostate Cancer Metastasis by Genomic Stratification (ERADICATE) (NCTNEA8183)
read more
This phase III trial compares the effect of adding darolutamide (Nubeqa, a type of hormonal therapy) to androgen deprivation therapy (ADT, a type of hormonal therapy) versus ADT alone after surgery for the treatment of high-risk prostate cancer. ADT reduces testosterone levels in the blood. Testosterone is a hormone made mainly in the testes and is needed to develop and maintain male sex characteristics, such as facial hair, deep voice, and muscle growth. It also plays role in prostate cancer development. Darolutamide blocks the actions of the androgens (e.g. testosterone) in the tumor cells and in the body. Giving darolutamide with ADT may work better in eliminating or reducing the size of the cancer and/or prevent it from returning compared to ADT alone in patients with prostate cancer.
This study has 2 treatment arms:
Arm A: ADT + placebo
Patients receive standard of care ADT (chosen by patient and treatment provider) PLUS placebo by mouth (PO, orally) 4 times daily for 52 weeks (1 year).
Arm B: ADT + darolutamide
Patient receive standard of care ADT (chosen by patient and treatment provider) PLUS darolutamide by mouth 4 times daily for 52 weeks.
|
JHUH | 0 |
Phase I/II First-in-Human Study of TT-10 as a Single Agent in Subjects With Advanced Selected Solid Tumors
read more
Multicenter, open-label dose-escalation Phase I/II clinical study, designed to evaluate the safety, tolerability, activity, anti-tumor activity, and effectiveness of TT-10 (a type of targeted therapy) in subjects diagnosed with advanced Renal cell cancer (RCC) and castrate resistant prostate cancer (CRPC) who have failed or are not eligible for standard of care treatment.
All patients will receive treatment with TT-10 orally administered (by mouth, po) twice daily starting at 10 mg and will be increased to 200 mg (additional dose levels maybe explored, if appropriate).
|
VCS | 0 |
An Evolutionary Double Bind Phase II Neoadjuvant Study of Abiraterone Acetate, Leuprolide Acetate, and Belzutifan in Men With Regional Prostate Cancer Eligible for Prostatectomy (J2258)
read more
For men with prostate cancer that involves the nearby lymph nodes standard treatment varies. Many men undergo radical prostatectomy (total removal of the prostate) along with the removal of nearby lymph nodes. Other men may opt for androgen deprivation therapy (ADT, a therapy that blocks testosterone, hormonal therapy) using the two drugs leuprolide and abiraterone (Zytiga) with or without radiation. This research is being done to investigate whether the use of leuprolide and abiraterone, when given in combination with a drug that blocks a molecule that senses oxygen needs by cancer cells, belzutifan (a type of targeted therapy), can kill cancer cells in the body prior in men who are planning on having the prostate surgically removed.
This study has one treatment arm. Participants will be treated with neoadjuvant (before surgery) therapy for a total of 3 months (12 weeks) prior to prostatectomy. Therapy will consist of leuprolide acetate, abiraterone acetate, and belzutifan.
Each drug will be dosed at its respective FDA-approved dosage. These dosages are as follows: leuprolide acetate one dose at 22.5 mg depot intramuscular injection, abiraterone acetate 1000 mg by mouth (orally, PO) once daily, and belzutifan120 mg administered by mouth once daily. All men will also be treated with prednisone 5 mg by mouth twice daily while on abiraterone acetate in order to reduce side effects.
|
JHUH | 0 |
A PHASE I DOSE ESCALATION AND EXPANDED COHORT STUDY OF PF-06821497 IN THE TREATMENT OF ADULT PATIENTS WITH RELAPSED/REFRACTORY SMALL CELL LUNG CANCER (SCLC), CASTRATION RESISTANT PROSTATE CANCER (CRPC) AND FOLLICULAR LYMPHOMA (FL)
read more
This is an open label, multi center, Phase 1 dose escalation study of PF 06821497 (a type of targeted therapy) administered orally as a single agent to patients with SCLC, CRPC, DLBCL and FL, or in combination with standard of care therapy (SOC).
This study has multiple treatment arms with multiple dose levels. All subjects will receive the study drug PF 06821497. Dose level and dosing schedule will be provided by your treatment team. Standard of care treatment will also be provided by your treatment team.
|
VCS | 0 |
Customized Ablation of the Prostate With the TULSA Procedure Against Radical Prostatectomy Treatment: a Randomized Controlled Trial for Localized Prostate Cancer (CAPTAIN) (J21133)
read more
The typical standard of care for patients with localized, intermediate risk prostate cancer is radical prostatectomy, which involves the surgical removal of the prostate. Although radical prostatectomy is effective in terms of controlling the cancer, it may leave men with significant long-term effects in urinary, sexual function like erectile dysfunction and/or incontinence (loss of bladder control), thus reducing quality of life. Preservation of continence (ability to control your bladder) and potency (ability to achieve erection and/or ejaculation) may be significant concerns for men.
Targeted ablation of localized prostate cancer using MRI-guided technology is becoming a favorable option for many men who wish to have their cancer treated but do not wish to compromise their urinary and sexual functions. The TULSA Procedure is a new, minimally invasive technique that uses real-time MRI-guided technology to guide the delivery of high-energy ultrasound to precisely, and in a customized fashion specific to you, heat and kill the prostate cancer tissue while protecting important surrounding body parts that are important for preserving urinary and sexual function. Minimally invasive here means that the procedure is performed through natural openings in your body (the urethra) instead of creating larger openings like traditional surgery or minimally invasive surgery.
This study has 2 treatment arms:
Arm A: Radical prostatectomy
If you are in this group, you will get the standard of care treatment used to treat this type of cancer: radical prostatectomy. You will undergo this procedure as per standard clinical practice. A radical prostatectomy is a surgical procedure that removes the prostate gland. This is done by making a surgical incision and removing the prostate gland.
Arm B: TULSA procedure
If you are in this group, you will get the TULSA Procedure. The TULSA Procedure is a minimally invasive procedure that uses directional ultrasound to produce very high temperature to ablate (destroy) targeted prostate tissue. The procedure is performed in an MRI suite (the physician can see the prostate at all times throughout the procedure) and uses the TULSA-PRO system to ablate prostate tissue. The procedure combines real-time MRI with robotically driven directional thermal ultrasound to deliver predictable, physician-prescribed ablation of the prostate. Minimally invasive here means that the procedure is performed through natural openings in your body (the urethra) instead of creating larger openings like in traditional surgery.
|
JHUH | 0 |
Phase 1b/2 Safety and Efficacy Study of NUV-422 in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
read more
NUV-422-04 (a type of targeted therapy) is an open-label Phase 1b/2 dose escalation and expansion study designed to evaluate the safety and effectiveness of NUV-422 in combination with enzalutamide (Xtandi, a type of hormonal therapy). The study population is comprised of adults with mCRPC.
All patients will receive treatment with NUV-422 (at various dose levels to be provided by the treatment team) and 160 mg enzalutamide orally (by mouth, po) in 28-day cycles. Patients will be treated until disease progression, toxicity, withdrawal of consent, or termination of the study.
|
VCS | 0 |
Phase 1, Two-part, Multicenter, Open-label, Multiple Dose, First-in-human Study of DS-1062a in Subjects With Advanced Solid Tumors (TROPION-PanTumor01) (J# pending)
read more
The primary purpose of this study is to investigate the safety and tolerability and to determine the maximum tolerated dose of DS-1062a (Datopotamab Deruxtecan, a type of targeted therapy). It is the first time the drug has been used in humans.
All subjects will receive treatment. DS-1062a is given intravenously (IV) in clinic. Dosing and schedule will be provided by the treatment team.
|
JHUH | 0 |
A Phase II Randomized Double Blinded Study of Green Tea Catechins (GTC) vs. Placebo in Men on Active Surveillance for Prostate Cancer: Modulation of Biological and Clinical Intermediate Biomarkers
read more
This phase II trial studies how well green tea catechins work in preventing progression of prostate cancer from a low risk stage to higher risk stages in men who are on active surveillance. Catechins are natural polyphenolic phytochemicals that exist in food and medicinal plants, such as tea. Green tea catechins may stabilize prostate cancer and lower the chance of prostate growing.
This study has 2 treatment arms:
Arm A: Green tea catechins
Patients receive green tea catechins by mouth (orally, PO) twice daily for up to 6 months in the absence of disease progression or unacceptable toxicity.
Arm B: Placebo
Patients receive placebo by mouth twice daily for up to 6 months.
|
WHC | 0 |
18F-DCFPyL PET/CT in High Risk and Recurrent Prostate Cancer
read more
Prostate cancer is the second leading cause of cancer deaths in American men. When prostate cancer is confined to the prostate there is a high chance of cure. However, if it is outside the prostate or comes back after treatment, additional therapy may be needed. Current methods of imaging prostate cancer are limited. Researchers want to see if a radiotracer called 18F-DCFPyL can identify prostate cancer in patients who have a high risk of cancer spreading outside the prostate or who have signs of recurrent cancer after treatment.
Participants will be divided into 2 groups:
Group 1 will be men with cancer that has been newly diagnosed as high risk by their doctor who are scheduled to have prostate removal surgery or undergo biopsy before radiation therapy.
Group 2 will be men who have presumed prostate cancer relapse after prostate removal surgery or radiation therapy.
Both groups will have scans taken. Participants will lie still on a table in a machine that takes pictures of their body. 18F-DCFyL will be injected by intravenous (IV) line.
Participants will be contacted for follow-up after scans.
There is no treatment given on this protocol.
|
NCI | 0 |
Phase 1/2 Study of REGN4336 (a PSMAXCD3 Bispecific Antibody) Administered Alone or in Combination With Cemiplimab in Patients With Metastatic Castration-Resistant Prostate Cancer
read more
Prostate cancer is the leading cause of new cancer diagnoses and the second most common cause of cancer-related death in American men. Prognosis is especially poor for men with metastatic castration resistant prostate cancer (mCRPC). Prostate-specific membrane antigen (PSMA) is highly expressed on malignant prostate tissue but shows limited expression on normal tissue. As such, PSMA is an excellent research target for treatment of mCRPC. REGN4336 is a PSMAxCD3 bispecific antibody designed to facilitate T-cell–mediated killing of PSMA-expressing tumor cells (a type of immunotherapy). In preclinical models, REGN4336 demonstrated strong PSMA-dependent antitumor activity. Preclinical data also support clinical research into the combination of REGN4336 with cemiplimab (Libtayo, another type of immunotherapy) for treating mCRPC.
This study has 2 treatment arms:
Arm A: REGN4336 alone
Administered once weekly (QW) or every 3 weeks (Q3W) by subcutaneous (SC) injection.
Arm B: REGN4336 + Cemiplimab
REGN4336 administered once weekly (QW) or every 3 weeks (Q3W) by subcutaneous (SC) injection PLUS Cemiplimab administered concomitantly every 3 weeks (Q3W) by intravenous (IV) infusion.
|
UMD | 0 |
A Multi-Center, Open-Label, Randomized Phase 2 Study of Copper Cu 64 PSMA I&T Injection in Patients With Histologically Proven Metastatic Prostate Cancer (J21135)
read more
This is a prospective, open-label Phase 2 study to evaluate copper Cu 64 PSMA I+T injection (a type of radiotracer or Radiolabeled Receptor-Targeted Diagnostic Product) for PET/CT imaging in patients with recurrent metastatic prostate cancer after radical prostatectomy or radiation therapy.
This study does not provide treatment. Each patient will be administered a 7-9 mCi intravenous (IV) dose of copper Cu 64 PSMA I+T injection. PET/CT images will be acquired for all patients at 1 hour and 4 hours post copper Cu 64 PSMA I+T injection.
|
JHUH | 0 |
Clinical Study of Bioactivity of Low Dose Apalutamide in Prostate Cancer Patients Scheduled for Prostatectomy (J2120)
read more
This trial investigates how well apalutamide (Erleada, a type of hormonal therapy) before surgery works in treating patients with prostate cancer that is confined to the prostate gland. Testosterone can cause the growth of prostate cancer cells. Apalutamide blocks the use of testosterone by the tumor cells. Giving low dose apalutamide before prostate surgery may lead to lowered PSA levels in men with prostate cancer that is confined to the prostate gland.
This study has 1 arm:
Apalutamide: The first 40 patients taking part in this trial receive apalutamide by mouth (orally or PO) 3 times per week for 4-8 weeks before prostate surgery in the absence of disease progression or unacceptable side effects. Based on PSA levels of the first 40 patients, the next group of 40 patients receive apalutamide either once per week or once daily for 4-8 weeks before prostate surgery in the absence of disease progression or unacceptable side effects. Patients may receive apalutamide for up to 12 weeks before prostate surgery (in the event surgery is delayed).
|
GWU, JHUH | 0 |
Phase 1/2 Safety and Efficacy Study of NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors
read more
NUV-868-01 (a type of targeted therapy) is a first-in human, open- label, Phase 1/2 dose escalation and expansion study in patients with advanced solid tumors. The Phase 1 portions include patients with advanced solid tumors and are designed to determine the safety and the dose(s) of NUV-868 to be used as monotherapy (single therapy) and in combination with olaparib (Lynparza, a type of targeted therapy) or enzalutamide (Xtandi, a type of hormonal therapy) for the Phase 2 portion. In Phase 2, NUV-868 in combination with olaparib or enzalutamide will be given to determine the safety and effectiveness of these study treatments.
This study has 4 possible treatment arms:
Arm A: NUV-868 alone
NUV-868 will be administered orally (by mouth, po) at escalating dose levels to be provided by the treatment team.
Arm B: NUV-868 + Olaparib
NUV-868 will be administered orally at escalating dose levels in combination with olaparib 300 mg administered orally twice daily throughout a 28 day cycle.
Arm C: NUV-868 + Enzalutamide
NUV-868 will be administered orally at escalating dose levels in combination with enzalutamide
160 mg administered orally daily throughout a 28 day cycle.
Arm D: Enzalutamide Monotherapy
Enzalutamide 160 mg will be administered orally once daily.
|
VCS | 0 |
A Phase 1 Open-label, Dose-finding Multi-center Trial of [177Lu]Ludotadipep in Metastatic Castration-resistant Prostate Cancer Patients, Followed by an Open-label, Repeat Dose, Multi-center Phase 2a Trial to Assess Safety and Efficacy
read more
The objective of the Phase 1 part of the clinical trial is to verify safety, tolerability, and maximum tolerated dose of [177Lu]Ludotadipep (a type of targeted radiation therapy) dose for use in the Phase 2 part of the trial.
The objective of the Phase 2 part of the trial is to evaluate safety and effectiveness for repeated administration of the recommended [177Lu]Ludotadipep.
All subjects will receive treatment.
Phase I: Patients will receive a single dose of [177Lu]Ludotadipep intravenously (IV)
Phase II: Patients will receive a dose of [177Lu]Ludotadipep intravenously every 8 weeks (4 to 6 times).
|
UMD | 0 |
Safety and Pharmacokinetics of ODM-208 in Patients With Metastatic Castration-resistant Prostate Cancer
read more
The purpose of this first-in-man study is to evaluate safety and tolerability of ODM-208 in patients with metastatic castration-resistant prostate cancer. ODM-208 is a type of targeted therapy. It is given in combination with two types of steroid therapy.
The study has 1 treatment arm:
ODM-208 co-administered with glucocorticoid and fludrocortisone, orally (by mouth or PO) once daily.
|
UMD | 0 |
A Phase III Double-Blind, Randomised, Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Docetaxel Versus Placebo + Docetaxel as Treatment for Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
read more
This study will assess the effectiveness and safety of capivasertib (a type of targeted therapy) plus docetaxel (Taxotere, a type of chemotherapy) versus placebo plus docetaxel in participants with metastatic castration resistant prostate cancer (mCRPC). All participants will receive the docetaxel with steroid therapy and receive androgen deprivation therapy. The intention of the study is to demonstrate that the combination of capivasertib plus docetaxel is superior to placebo plus docetaxel with respect to the overall survival of study participants, when overall survival is defined as the time from randomization until the date of death due to any cause.
This study has 2 treatment arms:
Arm A: Capivasertib + Docetaxel
Capivasertib 320 mg (2 tablets) given orally (by mouth or PO) on an intermittent weekly dosing schedule. Patients will be dosed on Days 2 to 5, 9 to 12, and 16 to 19 in each week of a 21-day treatment cycle until disease progression or unacceptable toxicity develops, death, or if the patient requests to stop the study treatment PLUS docetaxel given by intravenous (IV) infusion, 75 mg/m2 BSA, on Day 1 of the 21-day cycles for up to 6 to 10 cycles, according to standard of care practices.
Arm B: Placebo + Docetaxel
Placebo matched to capivasertib in appearance (2 tablets) given orally on an intermittent weekly dosing schedule. Patients will be dosed on Days 2 to 5, 9 to 12, and 16 to 19 in each week of a 21-day treatment cycle until disease progression or unacceptable toxicity develops, death, or if the patient requests to stop the study treatment PLUS docetaxel given by intravenous (IV) infusion, 75 mg/m2 BSA, on Day 1 of the 21-day cycles for up to 6 to 10 cycles, according to standard of care practices.
|
UMD | 0 |
Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk With Radiation (PREDICT-RT*)
read more
This trial compares less intense hormone therapy and radiation therapy to standard of care hormone therapy and radiation therapy in treating patients with high risk prostate cancer and a low gene risk score. This trial also compares more intense hormone therapy and radiation therapy to standard of care hormone therapy and radiation therapy in patients with high risk prostate cancer and a high gene risk score. Abiraterone acetate (Zytiga, a type of hormonal therapy) may help fight prostate cancer by lowering the amount of testosterone made by the body. Apalutamide (Erleada, a type of hormonal therapy) may help fight prostate cancer by blocking the use of androgen by the tumor cells. Radiation therapy uses high energy rays to kill tumor cells and shrink tumors. Giving a shorter hormone therapy treatment may work the same at controlling prostate cancer compared to the standard of care 24 month hormone therapy treatment in patients with a low gene risk score. Adding abiraterone acetate and apalutamide to the usual treatment may increase the length of time without prostate cancer spreading as compared to the usual treatment in patients with a high gene risk score.
This study has 3 treatment arms:
Arm A: Standard of care radiation (RT) + androgen deprivation therapy (ADT) for 24 months (De-Intensification)
Patients undergo RT over 4-9 weeks and receive ADT for 24 months in the absence of disease progression or unacceptable toxicity.
Arm B: RT + ADT for 12 months (De-Intensification)
Patients undergo RT over 4-9 weeks and receive ADT for 12 months in the absence of disease progression or unacceptable toxicity.
Arm C: RT + ADT + Apalutamide + Abiraterone with Prednisone (Intensification)
Patients undergo radiation therapy over 4-9 weeks and receive ADT (for 24 months in the absence of disease progression or unacceptable toxicity. Patients also receive apalutamide, abiraterone acetate and prednisone by mouth (PO or orally) once per day (QD). Treatment repeats every 90 days for up to 8 cycles (24 months) in the absence of disease progression or unacceptable toxicity.
|
INOVA, VCU | 0 |
Phase III Study of PET-Directed Local or Systemic Therapy Intensification in Prostate Cancer Patients With Post-Prostatectomy Biochemical Recurrence
read more
This phase III trial compares the addition of apalutamide (a type of hormonal therapy), with or without targeted radiation therapy, to standard of care treatment versus standard of care treatment alone in patients with prostate cancer biochemical recurrence (a rise in the blood level of prostate-specific antigen [PSA] after treatment with surgery or radiation). Diagnostic procedures, such as positron emission tomography/computed tomography (PET/CT), may help doctors look for cancer that has spread to the pelvis. Androgens can cause the growth of prostate cancer cells. Apalutamide may help fight prostate cancer by blocking the use of androgens by the tumor cells. Targeted radiation therapy uses high energy rays to kill tumor cells and shrink tumors that have spread. This trial may help doctors determine if using PET/CT results to deliver more tailored treatment (i.e., adding apalutamide, with or without targeted radiation therapy, to standard of care treatment) works better than standard of care treatment alone in patients with biochemical recurrence of prostate cancer.
This study has 4 treatment arms:
Arm A: PET scan plus standard of care radiation and hormonal therapy
Arm B: PET scan, standard of care radiation and hormonal therapy PLUS apalutamide by mouth (PO) once daily (QD) for 6 months in the absence of disease progression or unacceptable toxicity.
Arm C: PET scan, standard of care radiation and hormonal therapy PLUS apalutamide by mouth (PO) once daily (QD) for 6 months in the absence of disease progression or unacceptable toxicity. Patients randomized to this arm will receive an additional PET scan at 12 months (or at second rise in PSA).
Arm D: PET scan, standard of care radiation and hormonal therapy PLUS apalutamide by mouth (PO) once daily (QD) for 6 months in the absence of disease progression or unacceptable toxicity. Patients randomized to this arm also receive targeted radiation therapy over 3-5 fractions in the absence of disease progression or unacceptable toxicity.
|
VCU | 0 |
Randomized Phase III Trial Incorporating Abiraterone Acetate With Prednisone and Apalutamide and Advanced Imaging Into Salvage Treatment for Patients With Node-Positive Prostate Cancer After Radical Prostatectomy
read more
This phase III trial studies how well adding apalutamide (a type of hormonal therapy), abiraterone acetate (Zytiga, a type of hormonal therapy), and prednisone (a steroid) to the usual hormone therapy and radiation therapy works compared to the usual hormone therapy and radiation therapy in treating patients with node-positive prostate cancer after surgery. Radiation therapy uses high energy x-ray to kill tumor cells and shrink tumors. Androgens, or male sex hormones, can cause the growth of prostate cancer cells. Drugs, such as apalutamide, may help stop or slow the growth of prostate cancer cell growth by blocking the androgens. Abiraterone acetate blocks some of the enzymes needed for androgen production and may cause the death of prostate cancer cells that need androgens to grow. Prednisone may help abiraterone acetate work better by making tumor cells more sensitive to the drug. Adding apalutamide and abiraterone acetate with prednisone to the usual hormone therapy and radiation therapy after surgery may stabilize prostate cancer and prevent it from spreading or extend time without disease spreading compared to the usual approach.
This study has 2 treatment arms:
Arm A: Radiation and hormonal therapy (standard of care)
Patients receive standard of care hormone therapy per physician discretion for 24 months. Patients also undergo standard of care pelvis and prostate bed radiation therapy 5 days per week over 7-8 weeks beginning within 56 days after first hormone injection if the injection is not started prior to registration or within 90 days after first hormone injection if the injection is started prior to registration in the absence of disease progression or unacceptable toxicity.
Arm B: Radiation and hormonal therapy PLUS apalutamide, abiraterone acetate and prednisone
Patients receive standard of care hormone therapy and radiation therapy as in Arm A. Patients also receive apalutamide by mouth (PO) once daily (QD), abiraterone acetate PO QD, and
prednisone PO QD or BID (twice daily) on days 1-90. Cycles repeat every 90 days for 8 cycles in the absence of disease progression or unacceptable toxicity.
|
GWU, VCU | 0 |